Cytokinetics
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for its innovative cardiac drug, MYQORZO (aficamten). The approval clears the way for the treatment of adult patients suffering from symptomatic obstructive hypertrophic cardiomyopathy
